Celecoxib does not significantly alter the pharmacokinetics or hypoprothrombinemic effect of warfarin in healthy subjects

The objective of this study was to determine the effects of celecoxib, an anti-inflammarory/analgesic agent that primarily inhibits COX-2 and not COX-1 at therapeutic doses, on the steady-state pharmacokinetic profile and hypoprothrombinemic effect of racemic warfarin in healthy volunteers. Twenty-four healthy adult volunteers on maintenance doses of racemic warfarin (2-5 mg daily), stabilized to prothrombin times (PT) 1.2 to 1.7 times pretreatment PT values for 3 consecutive days, were randomized to receive concomirant celecoxib (200 mg bid) or placebo for 7 days in an open-label, multiple-dose, randomized, placebo-controlled parallel-group study of warfarin pharmacokinetics and PT: Steady-state exposure of S- and R-warfarin (area under the curve [AUC]) and maximum plasma concentration (C-max) in subjects receiving celecoxib were within 2% to 8% of the warfarin AUC and C-max in subjects receiving placebo during the concomitant treatment period. in addition, PT Values were not significantly different in subjects receiving warfarin and celecoxib concomitantly compared with subjects receiving warfarin and placebo, In conclusion, concomitant administration of celecoxib has no significant effect on PT or steady-state pharmacokinetics of S- or R-warfarin in healthy volunteers.